Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980441 | 0.97 | NPC1 (0.44) | NPC1RAB9AKDM4ETDP1MAP4K4 | |
| SCHEMBL25481646 | 0.94 | NPC1 (0.43) | NPC1RAB9AKDM4ETDP1MAP4K4 | |
| SCHEMBL17956061 | 0.92 | NPC1 (0.52) | NPC1RAB9AKDM4ETDP1ALDH1A1 | |
| SCHEMBL17955921 | 0.92 | MAOB (0.45) | NPC1RAB9AKDM4ETDP1ALDH1A1 | |
| SCHEMBL9980465 | 0.91 | KDM4E (0.47) | KDM4ETDP1ALDH1A1LMNACNR2 | |
| SCHEMBL17955897 | 0.91 | AKR1C3 (0.46) | NPC1RAB9AKDM4ETDP1ALDH1A1 | |
| SCHEMBL17956037 | 0.91 | KDM4E (0.41) | KDM4ETDP1ALDH1A1LMNACNR2 | |
| SCHEMBL17955923 | 0.91 | KDM4E (0.41) | NPC1RAB9AKDM4ETDP1ALDH1A1 | |
| SCHEMBL17955991 | 0.91 | DRD2 (0.46) | KDM4ETDP1ALDH1A1LMNACNR2 | |
| SCHEMBL17956031 | 0.90 | KDM1A (0.43) | MAPK14MDM2JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031359-A | Hydrogel for driving macrophage M1→M2 phenotype conversion and application thereof | 厦门大学 | 2026-05-15 | — | — | CN | claimed |
| US-12606802-B2 | Methods and compositions for improving the assembly of adeno-associated viruses (AAVs) | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2026-04-21 | — | — | US | claimed |
| CN-119925359-A | Application of Apoptozole in preparation of medicine for treating echinococcosis in multiple rooms | 新疆医科大学第一附属医院 | 2025-05-06 | — | — | CN | claimed |
| CN-119792530-A | Application of HSP70 inhibitor combined with sorafenib in treatment of mTOR activated liver cancer | 中国医学科学院基础医学研究所 | 2025-04-11 | — | — | CN | claimed |
| WO-2024212964-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING TUMORS, AND PHARMACEUTICAL COMBINATION AND USE THEREOF | 中国科学院分子细胞科学卓越创新中心 | 2024-10-17 | — | — | WO | claimed |
| CN-118662640-A | Pharmaceutical composition for preventing and/or treating tumor, pharmaceutical composition and application thereof | 中国科学院分子细胞科学卓越创新中心 | 2024-09-20 | — | — | CN | claimed |
| US-20230314438-A1 | SECRETED PHOSPHORYLATED HEAT SHOCK PROTEIN-70 AS A BIOMARKER FOR TREATING AND DIAGNOSING CANCER | UNIVERSITY OF CINCINNATI (US) | 2023-10-05 | — | — | US | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| US-20230201245-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | CZ BIOHUB SF, LLC | 2023-06-29 | — | — | US | claimed |
| CN-116120298-A | Stimulus-responsive nano-drug for low-temperature photothermal treatment | 青岛科技大学 | 2023-05-16 | — | — | CN | claimed |
| US-20230124862-A1 | BISMUTH THIOL COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATING MICROBIAL CO-INFECTIONS | MICROBION CORPORATION | 2023-04-20 | — | — | US | claimed |
| EP-4161646-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | Chan Zuckerberg Biohub, Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| EP-4127208-A1 | SECRETED PHOSPHORYLATED HEAT SHOCK PROTEIN-70 AS A BIOMARKER FOR TREATING AND DIAGNOSING CANCER | University of Cincinnati (US) | 2023-02-08 | — | — | EP | claimed |
| US-20220186193-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE ASSEMBLY OF ADENO-ASSOCIATED VIRUSES (AAVs) | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-06-16 | — | — | US | claimed |
| CN-114601844-A | Application of Hsp70 inhibitor in treating breast cancer | 四川大学华西医院 | 2022-06-10 | — | — | CN | claimed |
| CN-114364804-A | Methods and compositions for improving adeno-associated virus (AAV) assembly | 马萨诸塞眼科耳科诊所 | 2022-04-15 | — | — | CN | claimed |
| WO-2022072842-A1 | METHODS OF TREATING BONE INFECTIONS | MICROBION CORPORATION (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3953478-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE ASSEMBLY OF ADENO-ASSOCIATED VIRUSES (AAVS) | Massachusetts Eye and Ear Infirmary (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| CN-122031359-A | Hydrogel for driving macrophage M1→M2 phenotype conversion and application thereof | 厦门大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122031359-A | Hydrogel for driving macrophage M1→M2 phenotype conversion and application thereof | 厦门大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026088993-A1 | PRODUCTION METHOD FOR HEMATOPOIETIC STEM CELLS | 学校法人関西医科大学 | 2026-04-30 | — | — | WO | disclosed |
| US-12606802-B2 | Methods and compositions for improving the assembly of adeno-associated viruses (AAVs) | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260061064-A1 | CORRECTION OF ALZHEIMER'S DISEASE PATHOLOGY | NEUROTHER LLC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260061024-A1 | NASAL DELIVERY OF APIGENIN AND LINEAR PEPTIDE INHIBITORS OF MITOCHONDRIAL FISSION | NEUROTHER LLC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260061027-A1 | NASAL DELIVERY OF APIGENIN AND CYCLIC PEPTIDE INHIBITORS OF MITOCHONDRIAL FISSION | NEUROTHER LLC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2026049760-A1 | NASAL DELIVERY OF APIGENIN AND LINEAR PEPTIDE INHIBITORS OF MITOCHONDRIAL FISSION | NeuroTher, LLC (US) | 2026-03-05 | — | — | WO | disclosed |
| EP-3946437-B1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | H LEE MOFFITT CANCER CT & RES (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250339383-A1 | FUNCTIONAL POROSOME MANIPULATION | POROSOME THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250269031-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-28 | — | — | US | disclosed |
| US-20250223325-A1 | FUNCTIONAL POROSOME MANIPULATION | VIRON INC (US) | 2025-07-10 | — | — | US | disclosed |
| CN-120118070-A | Molecular chaperone HSP 70-mediated EML4-ALK targeted degradation agent, preparation method and application | 浙江大学 | 2025-06-10 | — | — | CN | disclosed |
| US-20250161287-A1 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES INC (US) | 2025-05-22 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119925359-A | Application of Apoptozole in preparation of medicine for treating echinococcosis in multiple rooms | 新疆医科大学第一附属医院 | 2025-05-06 | — | — | CN | disclosed |
| CN-119925359-A | Application of Apoptozole in preparation of medicine for treating echinococcosis in multiple rooms | 新疆医科大学第一附属医院 | 2025-05-06 | — | — | CN | disclosed |
| CN-119925359-A | Application of Apoptozole in preparation of medicine for treating echinococcosis in multiple rooms | 新疆医科大学第一附属医院 | 2025-05-06 | — | — | CN | disclosed |
| CN-119792530-A | Application of HSP70 inhibitor combined with sorafenib in treatment of mTOR activated liver cancer | 中国医学科学院基础医学研究所 | 2025-04-11 | — | — | CN | disclosed |
| EP-4512828-A2 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | Turnstone Biologics Corp. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119285649-A | Heterobifunctional compound based on HSP70 targeted degradation of BRD4, preparation and application | 中国药科大学 | 2025-01-10 | — | — | CN | disclosed |
| EP-4479745-A2 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | Vuja de Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240417685-A1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | MYST THERAPEUTICS, LLC (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4110799-B1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | TURNSTONE BIOLOGICS CORP (US) | 2024-11-06 | — | — | EP | disclosed |
| WO-2024220483-A2 | GRP78 CHIMERIC ANTIGEN RECEPTORS AND COMBINATION THERAPIES FOR TREATING CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024212964-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING TUMORS, AND PHARMACEUTICAL COMBINATION AND USE THEREOF | 中国科学院分子细胞科学卓越创新中心 | 2024-10-17 | — | — | WO | disclosed |
| US-20240316152-A1 | FUNCTIONAL POROSOME MANIPULATION | POROSOME THERAPEUTICS INC (US) | 2024-09-26 | — | — | US | disclosed |
| CN-118662640-A | Pharmaceutical composition for preventing and/or treating tumor, pharmaceutical composition and application thereof | 中国科学院分子细胞科学卓越创新中心 | 2024-09-20 | — | — | CN | disclosed |
| CN-118307432-A | Synthesis method of alpha-substituted amide compound | 南京工业大学 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4367518-A1 | FUNCTIONAL POROSOME MANIPULATION | Viron, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024035703-A1 | FUNCTIONAL POROSOME MANIPULATION | VIRON, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240053354-A1 | FUNCTIONAL POROSOME MANIPULATION | POROSOME THERAPEUTICS INC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| CN-114853676-B | Synthesis method of 1H-imidazole compound | 湖南第一师范学院 | 2023-11-17 | — | — | CN | disclosed |
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230314438-A1 | SECRETED PHOSPHORYLATED HEAT SHOCK PROTEIN-70 AS A BIOMARKER FOR TREATING AND DIAGNOSING CANCER | UNIVERSITY OF CINCINNATI (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023158783-A2 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20230201245-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | CZ BIOHUB SF, LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230152317-A1 | DIAGNOSIS AND TREATMENT OF COVID-19 | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| CN-116120298-A | Stimulus-responsive nano-drug for low-temperature photothermal treatment | 青岛科技大学 | 2023-05-16 | — | — | CN | disclosed |
| US-20230129866-A1 | METHODS OF TREATING RESPIRATORY DISEASE WITH DEUPIRFENIDONE | PURETECH LYT 100, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20230124862-A1 | BISMUTH THIOL COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATING MICROBIAL CO-INFECTIONS | MICROBION CORPORATION | 2023-04-20 | — | — | US | disclosed |
| EP-4161646-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | Chan Zuckerberg Biohub, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-111454177-B | Photo-induced non-adiabatic fading type photo-thermal material and preparation method and application thereof | 南方科技大学 | 2023-04-07 | — | — | CN | disclosed |
| EP-4127208-A1 | SECRETED PHOSPHORYLATED HEAT SHOCK PROTEIN-70 AS A BIOMARKER FOR TREATING AND DIAGNOSING CANCER | University of Cincinnati (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230032934-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | MYST THERAPEUTICS, LLC (US) | 2023-02-02 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-4110799-A1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | Myst Therapeutics, LLC (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115427438-A | Methods for ex vivo enrichment and expansion of tumor-reactive T cells and compositions related thereto | 迈斯特治疗公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-4065229-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | Myst Therapeutics, LLC (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115023270-A | Methods of generating tumor-reactive T cell compositions using modulators | 迈斯特治疗公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-112618542-B | Use of HSP70 inhibitors for broad spectrum anti-flavivirus activity | 中国人民解放军军事科学院军事医学研究院 | 2022-08-09 | — | — | CN | disclosed |
| CN-114853676-A | Synthesis method of 1H-imidazole compound | 湖南第一师范学院 | 2022-08-05 | — | — | CN | disclosed |
| EP-4031543-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220186193-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE ASSEMBLY OF ADENO-ASSOCIATED VIRUSES (AAVs) | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| CN-114601844-A | Application of Hsp70 inhibitor in treating breast cancer | 四川大学华西医院 | 2022-06-10 | — | — | CN | disclosed |
| CN-114601844-A | Application of Hsp70 inhibitor in treating breast cancer | 四川大学华西医院 | 2022-06-10 | — | — | CN | disclosed |
| US-20220177841-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | MYST THERAPEUTICS LLC (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2022115443-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
| CN-114364804-A | Methods and compositions for improving adeno-associated virus (AAV) assembly | 马萨诸塞眼科耳科诊所 | 2022-04-15 | — | — | CN | disclosed |
| CN-114269370-A | Methods of ex vivo production of T cell therapeutics and related compositions and methods | 迈斯特治疗公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3952914-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) | 2022-02-16 | — | — | EP | disclosed |
| EP-3953478-A1 | METHODS AND COMPOSITIONS FOR IMPROVING THE ASSEMBLY OF ADENO-ASSOCIATED VIRUSES (AAVS) | Massachusetts Eye and Ear Infirmary (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | disclosed |
| EP-3946437-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | Myst Therapeutics, LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021183474-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-09-16 | — | — | WO | disclosed |
| EP-3050875-B1 | NOVEL IMIDAZOLE DERIVATIVE AND THERAPEUTICAL USE THEREOF | UNIV YONSEI IACF (KR) | 2019-03-13 | — | — | EP | disclosed |
| US-20160297768-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THERAPEUTIC USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-10-13 | — | — | US | disclosed |
| EP-3050875-A1 | NOVEL IMIDAZOLE DERIVATIVE AND THERAPEUTICAL USE THEREOF | Industry-Academic Cooperation Foundation, Yonsei University (KR) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015046647-A1 | NOVEL IMIDAZOLE DERIVATIVE AND THERAPEUTICAL USE THEREOF | 연세대학교 산학협력단 | 2015-04-02 | — | — | WO | disclosed |
| US-8163791-B2 | Imidazole derivatives that induce apoptosis and their therapeutic uses | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-04-24 | — | — | US | disclosed |
| US-8163791-B2 | Imidazole derivatives that induce apoptosis and their therapeutic uses | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-04-24 | — | — | US | disclosed |
| US-8163791-B2 | Imidazole derivatives that induce apoptosis and their therapeutic uses | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-04-24 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, RPS27A, HSPBP1 | NPC1 3090/4885RAB9A 2121/4885KDM4E 2583/4885 |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | MMP1, MMP8, CCL11 | NPC1 2016/4885RAB9A 1898/4885KDM4E 3729/4885 |
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | RECQL, NQO1, BRD4 | NPC1 29/4885RAB9A 959/4885KDM4E 2089/4885 |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | NFATC1, AIFM1, TP53 | NPC1 177/4885RAB9A 1495/4885KDM4E 3985/4885 |
| US-20160297768-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THERAPEUTIC USE THEREOF | TP53, BAD, API5 | NPC1 1082/4885RAB9A 2597/4885KDM4E 1678/4885 |
| US-20260061027-A1 | NASAL DELIVERY OF APIGENIN AND CYCLIC PEPTIDE INHIBITORS OF MITOCHONDRIAL FISSION | NLN, FIS1, APP | NPC1 328/4885RAB9A 1454/4885KDM4E 4525/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | NPC1 4802/4885RAB9A 4071/4885KDM4E 1756/4885 |
| US-20250269031-A1 | MITOCHONDRIA TARGETING QUINOLINIUM-DRUG CONJUGATES AND THEIR SELF-ASSEMBLING NANOFORMULATIONS FOR CANCER THERAPY | MFN2, UQCRC2, UQCRC1 | NPC1 2073/4885RAB9A 501/4885KDM4E 2516/4885 |
| US-20230124862-A1 | BISMUTH THIOL COMPOUNDS AND COMPOSITIONS AND METHODS OF TREATING MICROBIAL CO-INFECTIONS | MPST, TST, TPMT | NPC1 2166/4885RAB9A 2049/4885KDM4E 3079/4885 |
| US-20260061064-A1 | CORRECTION OF ALZHEIMER'S DISEASE PATHOLOGY | ATP6V1B2, TARDBP, TAP1 | NPC1 290/4885RAB9A 2099/4885KDM4E 4512/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | NPC1 528/4885RAB9A 146/4885KDM4E 3590/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | NPC1 4433/4885RAB9A 2426/4885KDM4E 448/4885 |
| US-12606802-B2 | Methods and compositions for improving the assembly of adeno-associated viruses (AAVs) | HSP90AB2P, HSP90AB1, HSPA2 | NPC1 377/4885RAB9A 1431/4885KDM4E 3138/4885 |
| US-20230129866-A1 | METHODS OF TREATING RESPIRATORY DISEASE WITH DEUPIRFENIDONE | ACE2, PPARD, ACE | NPC1 3795/4885RAB9A 2127/4885KDM4E 1024/4885 |
| US-20260061024-A1 | NASAL DELIVERY OF APIGENIN AND LINEAR PEPTIDE INHIBITORS OF MITOCHONDRIAL FISSION | FIS1, OPA1, STOML2 | NPC1 188/4885RAB9A 2117/4885KDM4E 4678/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | NPC1 4802/4885RAB9A 4071/4885KDM4E 1756/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | NPC1 528/4885RAB9A 146/4885KDM4E 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.